The maternal mortality rate is one of the three comprehensive indicators for measuring national health and social progress recognized in the world. However, the current society still pays insufficient attention to the death of pregnant women, such as2The death toll of pregnant women in my country reached 3550 in 2016.In the same period, the number of deaths from air crashes in the world was 268. In comparison, my country's attention to maternal deaths still needs to be improved.
To achieve the maternal mortality rate in 2030 from the current18.3 per 100,000 are reduced to 12 per 100,000, and the average female life expectancy has increased from 76.3 to 79 years. At the same time, the quality of the birth population is further improved. This requires our first-line obstetricians and gynecologists to update their concepts, strengthen business training, and absorb successful knowledge , And strive to improve work ability and level.
The 4th Maternal Fetal Medicine Conference of the Chinese Medical Doctor Association officially opened in Xi’an on July 5,the conference invited nearly 100 well-known experts in maternal and fetal medicine from Canada, the United States and China to discuss new developments and hot issues in maternal and fetal medicine.
It was pointed out at the meeting that among all the deaths of pregnant women, 10.4% were caused by pregnancy-induced hypertension and related diseases, which was one of the main causes of maternal deaths.Pregnancy-induced hypertensionandpreeclampsia the degree of attention is also increasing.
During the conference, Professor Zheng Boren from Chang Gung Memorial Hospital in Taiwan proposed the new evidence of early-onset preeclampsia warning indicators points out the important role of Bayesian model in assessing preeclampsia.
Professor Zheng Jianlan from the Chenggong Hospital of Xiamen University pointed out that with the increasing attention of PlGF in recent years, the importance of PlGF in the management of preeclampsia is increasingly recognized.Clinically,risk stratification of pregnant women can be carried out through changes in the content of PlGF，It indicates the risk of preeclampsia during pregnancy, and provides corresponding suggestions for clinical intervention and treatment.
In this conference, Ningbo Aucheer was also invited to participate. At the same time, Aucheer also brought the latest testing platform and testing reagents independently developed to bring more solutions for the diagnosis and treatment of women and children's health.
Ningbo Aocheng
Ningbo Aocheng Biotechnology Co., Ltd. is a high-tech biological enterprise focusing on the early detection, diagnosis, prevention and monitoring of diseases. By providing reliable, fast and convenient in vitro diagnostic products, we can provide accurate test results for diagnosis and treatment. Committed to providing professional clinical diagnosis solutions for women and children's health.
辨荧光免疫定量检测系统
iRaTe 300 Single Channel Fluorescence Immunoassay Analyzer
iRaTe 1600 Multi-channel Fluorescence Immunoassay Analyzer
Instrument Characteristics
Convenient：血清、血浆或全血均可
Automatic：可实现自动进卡、弃卡
Fast：12min完成首次检测
Stablize：CV≤10%
Linear：r≥0.99
Speed Measurement：30-60T/h
Aucheer iRaTe PlGF Detection Reagent
The Aucheer iRate PlGF test reagent can help clinicians more reasonably carry out risk stratification and clinical assessment of high-risk factors and pregnant women with suspected preeclampsia, strengthen the management of preeclampsia, reduce or delay the occurrence and development of preeclampsia, and ensure the safety of mothers and fetuses.
● Methodology：Fluorescence immunoassay
● Linear Range：12-3000pg/mL
● Specimen Type：血清、血浆或全血
● Accuracy：CV≤15%
● Detection Time：12min
● Can be connected to the LIS system in the hospital
